Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Panobinostat (LBH589) in Patients With Metastatic Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Brigham and Women's Hospital
Novartis
Information provided by (Responsible Party):
F. Stephen Hodi, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01065467
First received: February 8, 2010
Last updated: November 16, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)